Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) has a new shareholder in the form of Bihua Chen‘s Cormorant Asset Management. As per a new 13G filing with the Securities and Exchange Commission, the fund has acquired 1 million common shares of the company, which represent 5.14% of the float. According to its 13F filing for the end of the second quarter, the fund held no shares of Sunesis Pharmaceuticals at the end of June.
As its name suggests, Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) is a clinical-stage biopharmaceutical company that is working on the production of its pipeline of oncology therapeutics. Cormorant’s acquisition of shares comes a couple of weeks after the company announced a spot secondary offering of 4.936 million shares at $3.85 per share, which could be what opened the door for Cormorant to build its position. Over the past 12 months, the company’s stock has lost 29.92%. For the second quarter of 2016, Sunesis Pharmaceuticals reported a loss per share of $0.12 and revenue of $0.61 million, both of which missed expectations of a loss per share of $0.10 and revenue of $1.04 million.
RAJ CREATIONZS / shutterstock.com
11 hedge funds from within Insider Monkey’s database reported having long positions in Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) as of the end of June, up by two from a quarter earlier. Among the investors with the largest positions were Jeffrey Jay and David Kroin’s Great Point Partners (8.17 million shares), William Leland Edwards’ Palo Alto Investors (6.97 million shares), Julian Baker and Felix Baker’s Baker Bros. Advisors (4.45 million shares), and Richard Driehaus’ Driehaus Capital (1.95 million shares).
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
You can access the original SEC filing by clicking here.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Cormorant Global Healthcare Master Fund | 0 | 831,500 | 0 | 831,500 | 831,500 | 4.28% |
| Cormorant Global Healthcare GP | 0 | 831,500 | 0 | 831,500 | 831,500 | 4.28% |
| Cormorant Asset Management | 0 | 1,000,000 | 0 | 1,000,000 | 1,000,000 | 5.14% |
| Bihua Chen | 0 | 1,000,000 | 0 | 1,000,000 | 1,000,000 | 5.14% |
Follow Bihua Chen's Cormorant Asset Management
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 10 – SEC Filing
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | OMB APPROVAL | |
| OMB Number:3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 |
| SCHEDULE 13G | ||
| Under the Securities Exchange Act of 1934 | ||
| (Amendment No. ___)* |
| Sunesis Pharmaceuticals, Inc. | ||
| (Name of Issuer) |
| Common Stock, par value $0.0001 per share | ||
| (Title of Class of Securities) |
| 867328502 | ||
| (CUSIP Number) |
| October 19, 2016 | ||
| (Date of Event which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
___________________________________
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 2 of 10 – SEC Filing
| CUSIP NO. | 867328502 |
| 1 | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Cormorant Global Healthcare Master Fund, LP | |
| 2 | Check the Appropriate Box if a Member of a Group (See Instructions) | |
| (a) [ ] | ||
| (b) [x] | ||
| 3 | SEC Use Only | |
| 4 | Citizenship or Place of Organization. Cayman Islands | |
| Number of Shares Beneficially Owned by Each Reporting Person With | 5 Sole Voting Power 0 shares | |
| 6 Shared Voting Power 831,500 shares Refer to Item 4 below. | ||
| 7 Sole Dispositive Power 0 shares | ||
| 8 Shared Dispositive Power 831,500 shares Refer to Item 4 below. | ||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person 831,500 shares Refer to Item 4 below. | |
| 10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A | |
| 11 | Percent of Class Represented by Amount in Row (9)* 4.28% Refer to Item 4 below. | |
| 12 | Type of Reporting Person (See Instructions) PN (Partnership) | |
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 3 of 10 – SEC Filing
| CUSIP NO. | 867328502 |
| 1 | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Cormorant Global Healthcare GP, LLC | |
| 2 | Check the Appropriate Box if a Member of a Group (See Instructions) | |
| (a) [ ] | ||
| (b) [x] | ||
| 3 | SEC Use Only | |
| 4 | Citizenship or Place of Organization. Delaware | |
| Number of Shares Beneficially Owned by Each Reporting Person With | 5 Sole Voting Power 0 shares | |
| 6 Shared Voting Power 831,500 shares Refer to Item 4 below. | ||
| 7 Sole Dispositive Power 0 shares | ||
| 8 Shared Dispositive Power 831,500 shares Refer to Item 4 below. | ||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person 831,500 shares Refer to Item 4 below. | |
| 10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A | |
| 11 | Percent of Class Represented by Amount in Row (9)* 4.28% Refer to Item 4 below. | |
| 12 | Type of Reporting Person (See Instructions) OO (Limited Liability Company) | |
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 4 of 10 – SEC Filing
| CUSIP NO. | 867328502 |
| 1 | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Cormorant Asset Management, LLC | |
| 2 | Check the Appropriate Box if a Member of a Group (See Instructions) | |
| (a) [ ] | ||
| (b) [x] | ||
| 3 | SEC Use Only | |
| 4 | Citizenship or Place of Organization. Delaware | |
| Number of Shares Beneficially Owned by Each Reporting Person With | 5 Sole Voting Power 0 shares | |
| 6 Shared Voting Power 1,000,000 shares Refer to Item 4 below. | ||
| 7 Sole Dispositive Power 0 shares | ||
| 8 Shared Dispositive Power 1,000,000 shares Refer to Item 4 below. | ||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person 1,000,000 shares Refer to Item 4 below. | |
| 10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A | |
| 11 | Percent of Class Represented by Amount in Row (9)* 5.14% Refer to Item 4 below. | |
| 12 | Type of Reporting Person (See Instructions) OO (Limited Liability Company) | |
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 5 of 10 – SEC Filing
| CUSIP NO. | 867328502 |
| 1 | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Bihua Chen | |
| 2 | Check the Appropriate Box if a Member of a Group (See Instructions) | |
| (a) [ ] | ||
| (b) [x] | ||
| 3 | SEC Use Only | |
| 4 | Citizenship or Place of Organization. United States | |
| Number of Shares Beneficially Owned by Each Reporting Person With | 5 Sole Voting Power 0 shares | |
| 6 Shared Voting Power 1,000,000 shares Refer to Item 4 below. | ||
| 7 Sole Dispositive Power 0 shares | ||
| 8 Shared Dispositive Power 1,000,000 shares Refer to Item 4 below. | ||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person 1,000,000 shares Refer to Item 4 below. | |
| 10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A | |
| 11 | Percent of Class Represented by Amount in Row (9)* 5.14% Refer to Item 4 below. | |
| 12 | Type of Reporting Person (See Instructions) IN (Individual) | |
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 6 of 10 – SEC Filing
| CUSIP NO. | 867328502 |
Item 1.
| (a) | Name of Issuer | |
| Sunesis Pharmaceuticals, Inc. | ||
| (b) | Address of Issuer’s Principal Executive Offices | |
| 395 Oyster Point Boulevard, Suite 400 South San Francisco, CA 94080 |
Item 2.
| (a) | Name of Person Filing | |
| Cormorant Global Healthcare Master Fund, LP Cormorant Global Healthcare GP, LLC Cormorant Asset Management, LLC Bihua Chen | ||
| (b) | Address of Principal Business Office or, if none, Residence | |
| 200 Clarendon Street, 52nd Floor Boston, MA 02116 | ||
| (c) | Citizenship | |
| Cormorant Global Healthcare Master Fund, LP – Cayman Islands Cormorant Global Healthcare GP, LLC – Delaware Cormorant Asset Management, LLC – Delaware Bihua Chen – United States | ||
| (d) | Title of Class of Securities | |
| Common Stock | ||
| (e) | CUSIP Number 867328502 | |
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 7 of 10 – SEC Filing
| CUSIP NO. | 867328502 |
| Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
| (a) | [ ] | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). | |
| (b) | [ ] | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). | |
| (c) | [ ] | Insurance Company as defined in Section 3(a)(19) of the Act | |
| (d) | [ ] | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). | |
| (e) | [ ] | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); | |
| (f) | [ ] | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); | |
| (g) | [ ] | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); | |
| (h) | [ ] | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); | |
| (i) | [ ] | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); | |
| (j) | [ ] | A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J); | |
| (k) | [ ] | Group, in accordance with §240.13d-1(b)(1)(ii)(K). |
| Item 4. | Ownership*** |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
| (a) | Amount Beneficially Owned*** | ||
| Cormorant Global Healthcare Master Fund, LP – 831,500 shares Cormorant Global Healthcare GP, LLC – 831,500 shares Cormorant Asset Management, LLC – 1,000,000 shares Bihua Chen – 1,000,000 shares | |||
| (b) | Percent of Class | ||
| Cormorant Global Healthcare Master Fund, LP – 4.28% Cormorant Global Healthcare GP, LLC – 4.28% Cormorant Asset Management, LLC – 5.14% Bihua Chen – 5.14% | |||
| (c) | Number of shares as to which such person has: | ||
| (i) | sole power to vote or to direct the vote Cormorant Global Healthcare Master Fund, LP – 0 shares Cormorant Global Healthcare GP, LLC – 0 shares Cormorant Asset Management, LLC – 0 shares | ||
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 8 of 10 – SEC Filing
| CUSIP NO. | 867328502 |
| Bihua Chen – 0 shares | |||
| (ii) | shared power to vote or to direct the vote | ||
| Cormorant Global Healthcare Master Fund, LP – 831,500 shares Cormorant Global Healthcare GP, LLC – 831,500 shares Cormorant Asset Management, LLC – 1,000,000 shares Bihua Chen – 1,000,000 shares | |||
| (iii) | sole power to dispose or to direct the disposition of | ||
| Cormorant Global Healthcare Master Fund, LP – 0 shares Cormorant Global Healthcare GP, LLC – 0 shares Cormorant Asset Management, LLC – 0 shares Bihua Chen – 0 shares | |||
| (iv) | shared power to dispose or to direct the disposition of | ||
| Cormorant Global Healthcare Master Fund, LP – 831,500 shares Cormorant Global Healthcare GP, LLC – 831,500 shares Cormorant Asset Management, LLC – 1,000,000 shares Bihua Chen – 1,000,000 shares |
*** Shares reported herein for Cormorant Asset Management, LLC represent shares which are beneficially owned by Cormorant Global Healthcare Master Fund, LP (the “Fund”), as reported herein, and shares which are beneficially owned by a managed account (the “Account”). Cormorant Global Healthcare GP, LLC serves as the general partner of the Fund, and Cormorant Asset Management, LLC serves as the investment manager to both the Fund and the Account. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC and Cormorant Asset Management, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein.
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
Not applicable.
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 9 of 10 – SEC Filing
| CUSIP NO. | 867328502 |
| Item 8. | Identification and Classification of Members of the Group |
Not applicable.
| Item 9. | Notice of Dissolution of Group |
Not applicable.
| Item 10. | Certification |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 10 of 10 – SEC Filing
| CUSIP NO. | 867328502 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
October 31, 2016
| CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP | |
| By: Cormorant Global Healthcare GP, LLC its General Partner | |
| By: /s/ Bihua Chen | |
| Bihua Chen, Managing Member | |
| CORMORANT GLOBAL HEALTHCARE GP, LLC | |
| By: /s/ Bihua Chen | |
| Bihua Chen, Managing Member | |
| CORMORANT ASSET MANAGEMENT, LLC | |
| By: /s/ Bihua Chen | |
| Bihua Chen, Managing Member | |
| /s/ Bihua Chen | |
| Bihua Chen |
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
